IVMP therapy not only reduced the mRNA levels of IFNG but also GLUT3, SLC7A5, and LDHA, confirming that therapeutically applied GCs repress genes involved in the energy metabolism of T cells in MS patients with a progressive disease course (Figure 7C). This evidence concerns the gene SLC2A3 and myeloid sarcoma.